Mechanisms of Action and Clinical Development of Elotuzumab

Clin Transl Sci. 2018 May;11(3):261-266. doi: 10.1111/cts.12532. Epub 2017 Dec 22.

Authors

David Ritchie¹, Marco Colonna²

Affiliations

¹ Royal Melbourne Hospital, Melbourne, Victoria, Australia.
² Washington University School of Medicine, St Louis, Missouri, USA.

No abstract available

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic
Drug Development / methods*
Humans
Kaplan-Meier Estimate
Killer Cells, Natural / drug effects
Killer Cells, Natural / immunology
Lymphocyte Activation / drug effects
Lymphocyte Activation / immunology
Multiple Myeloma / drug therapy*
Multiple Myeloma / etiology
Multiple Myeloma / immunology
Multiple Myeloma / mortality
Progression-Free Survival
Signal Transduction / drug effects
Signaling Lymphocytic Activation Molecule Family / antagonists & inhibitors*
Signaling Lymphocytic Activation Molecule Family / metabolism
Survival Rate

Substances

Antibodies, Monoclonal, Humanized
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
elotuzumab